Remnant cholesterol as a causal risk factor for ischemic heart disease.

[1]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[2]  B. Nordestgaard,et al.  LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. , 2012, The Journal of clinical endocrinology and metabolism.

[3]  P. Toth.  LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individuals , 2012 .

[4]  William Weintraub,et al.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[5]  P. Schnohr,et al.  Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow‐up , 2011, Journal of internal medicine.

[6]  Moshe Levi,et al.  Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. , 2011, Circulation.

[7]  J. Borén,et al.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[8]  B. Nordestgaard,et al.  Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk , 2011, Current opinion in lipidology.

[9]  B. Nordestgaard,et al.  Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population , 2011, Annals of neurology.

[10]  B. Nordestgaard,et al.  TRIB1 and GCKR Polymorphisms, Lipid Levels, and Risk of Ischemic Heart Disease in the General Population , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[11]  Børge G Nordestgaard,et al.  PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. , 2010, Journal of the American College of Cardiology.

[12]  G. Moneta,et al.  Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .

[13]  B. Nordestgaard,et al.  Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. , 2009, The Journal of clinical endocrinology and metabolism.

[14]  B. Nordestgaard,et al.  Nonfasting hyperlipidemia and cardiovascular disease. , 2009, Current drug targets.

[15]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of ischemic stroke in the general population. , 2008, JAMA.

[16]  Børge G Nordestgaard,et al.  Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. , 2008, JAMA.

[17]  George Davey Smith,et al.  Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology , 2008, Statistics in medicine.

[18]  Dolores Corella,et al.  Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans , 2008, Nature Genetics.

[19]  N. Timpson,et al.  Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization , 2008, Annals of medicine.

[20]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[21]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[22]  P. Ridker,et al.  Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. , 2007, JAMA.

[23]  K. Nakajima,et al.  The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[24]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[25]  Takamitsu Nakamura,et al.  Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. , 2005, Atherosclerosis.

[26]  A. Takeshita,et al.  Postprandial Increase in Plasma Concentrations of Remnant-Like Particles: An Independent Risk Factor for Restenosis after Percutaneous Coronary Intervention , 2004, Journal of cardiovascular pharmacology.

[27]  K. Kugiyama,et al.  Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. , 2004, Journal of the American College of Cardiology.

[28]  K. Ishii,et al.  High remnant lipoprotein levels in patients with variant angina , 2004, Clinical cardiology.

[29]  T. Inoue,et al.  Remnant-like lipoprotein particles as risk factors for coronary artery disease in elderly patients. , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[30]  K. Kugiyama,et al.  Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease. , 2001, The American journal of cardiology.

[31]  A. Hamsten,et al.  Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. , 2001, Journal of lipid research.

[32]  P. Wilson,et al.  Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. , 2001, Atherosclerosis.

[33]  H. Masuoka,et al.  Predictive value of remnant-like particle cholesterol as an indicator of coronary artery stenosis in patients with normal serum triglyceride levels. , 2000, Internal medicine.

[34]  H. Masuoka,et al.  Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels. , 2000, American heart journal.

[35]  Jin Q. Kim,et al.  Remnant-Like Particle Cholesterol Levels in Korean Patients with Coronary Artery Disease and Non-Insulin Dependent Diabetes Mellitus , 2000, Clinical chemistry and laboratory medicine.

[36]  R. Collins,et al.  Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. , 1999, American journal of epidemiology.

[37]  H Yasue,et al.  Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. , 1999, Circulation.

[38]  K. Nakajima,et al.  Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death. , 1999, Atherosclerosis.

[39]  H. Masuoka,et al.  Predictive value of remnant-like particles cholesterol/high-density lipoprotein cholesterol ratio as a new indicator of coronary artery disease. , 1998, American heart journal.

[40]  P. Schnohr,et al.  Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. , 1998, The New England journal of medicine.

[41]  S. Grundy,et al.  Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease. , 1998, The American journal of medicine.

[42]  M. Shirotani,et al.  Remnant-like particle cholesterol is a major risk factor for myocardial infarction in vasospastic angina with nearly normal coronary artery. , 1998, Atherosclerosis.

[43]  R. Wootton,et al.  Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[44]  R. Wootton,et al.  Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.